Skip to content

L-menthol as a Topical Counter-irritant to TRPA1-induced Neurogenic Inflammation and Pain

High-concentration L-menthol as a Counter-irritant to TRPA1-induced Neurogenic Inflammation, Thermal and Mechanical Hyperalgesia Caused by Trans-cinnamaldehyde

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02653703
Enrollment
14
Registered
2016-01-12
Start date
2014-10-31
Completion date
2014-12-31
Last updated
2016-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperalgesia, Inflammation, Pruritus

Brief summary

The aim of this study is to quantitatively characterize the effects of L-menthol as a topical counter-irritant on cutaneous pain and hyperalgesia provoked by topical application of the TRPA1-agonist trans-cinnamaldehyde (CA) in healthy human volunteers.

Detailed description

This study is designed as an experimental model in healthy humans.

Interventions

OTHERVehicle, topical ethanol 96%

Organic solvent CAS Number: 64-17-5

OTHERTopical L-menthol 40%

Naturally occurring local anaesthetic, counterirritant and TPRM8-agonist. CAS Number: 2216-51-5

Sponsors

Aalborg University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* 18 healthy men and women aged 18-50 years willing to abstain from alcohol, nicotine, caffeine and pain medication 24 hours before experimental sessions

Exclusion criteria

* Pregnancy * Skin disorders (e.g. contact eczema) * Chronic pain conditions * Drug addiction defined as the use of cannabis, opioids or other drugs * Previous neurologic, musculoskeletal or mental illnesses * Lack of ability to cooperate

Design outcomes

Primary

MeasureTime frameDescription
Spontaneous pain intensity [self-reported on a visual analog scale]0-20 minutes with a sampling frequency of 1/1 minRating of the overall pain intensity on a visual analog scale (VAS ranging from No pain = 0, to worst imaginable pain =10) once every minute

Secondary

MeasureTime frameDescription
Neurogenic inflammation [Measured by Laser speckle flowmetry in a 3x3 cm area]20-25 minutes post inductionSpeckle contrast flowmetry (MoorFLPI, Moor Instruments, Devon, UK). The assessment is conducted with a 30-cm distance between the head of the laser and the application area with an exposure time of 8.3ms. Single frame images are analyzed on appertaining software (MoorFLPI Review V 4.0, Moor Instruments), upon which the arithmetic mean flux (arbitrary units) is calculated. The longitudinal analysis of the spatial dispersion of neurogenic inflammation is performed using the line histogram tool. A 7-cm line centered in the area of application was placed longitudinally along the volar forearm and the perfusion intensity is recorded every 2.5 mm.
Heat hyperalgesia25-27.5 minutes post inductionHeat pain threshold assessments is performed with a Medoc Pathway (Medoc Ltd, Ramat Yishay, Israel) equipped with a 3 × 3 cm advanced thermal stimulator probe where the baseline temperature was set to 32 °C. Ramp stimuli of 1 °C/s are delivered and the subjects are asked to identify the heat pain threshold upon which the temperature is returned to the baseline at a rate of 5 °C/s. The test result is calculated as the arithmetic mean of the outcome from three repeated stimuli. Heat hyperalgesia is considered to be a significant drop in heat pain threshold
Mechanical hyperalgesia27.5-30 minutes post inductionTo evaluate the mechanical pain threshold (MPT) an electronic von Frey transducer and an electronic coVAS connected to a SENSE-Box setup is used (both items: Somedic, Hörby, Sweden). Five ramp stimuli from 0-110 g at a rate of 5g/1 sec with the default stimulus probe is conducted at different locations within the application area. The subjects are instructed to continuously rate the perceived pain on the coVAS ranging from No pain (0) to worst imaginable pain (10). The arithmetic mean of the VAS scores yields three MPTs (fixed to VAS = 0.5, 1 and 2) and an area-under-the-curve (AUC).

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 13, 2026